Physician profile
Manojkumar Singh
NPI 1295934719
$5,922.08
in general payments reported to CMS, 2019-2025
28 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $283 · 2021: $897 · 2022: $1,458 · 2023: $911 · 2024: $936 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.53 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,125.23 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Regeneron Healthcare Solutions, INC. | $586.60 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $574.26 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $528.74 | 2019-2023 | Entyvio |
| Medtronic, INC. | $282.39 | 2022-2025 | Interstim, Gi Genius |
| Madrigal Pharmaceuticals | $244.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $225.84 | 2019-2020 | |
| Celgene Corporation | $184.82 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $146.28 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $137.57 | 2020-2024 | |
| Gilead Sciences, INC. | $105.49 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $102.85 | 2023-2024 | Rebyota |
| Janssen Scientific Affairs, LLC | $100.69 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.57 | 2022-2025 | Xifaxan |
| Genzyme Corporation | $91.39 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $89.25 | 2021-2022 | |
| Pfizer INC. | $72.79 | 2022-2025 | |
| Lilly USA, LLC | $69.10 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $23.11 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $23.00 | 2024 | |
| Vivus LLC | $19.57 | 2024 | Qsymia |
| Amgen INC. | $16.26 | 2023 | Avsola |
| Braintree Laboratories, INC. | $16.11 | 2023 | Sutab |
| Dexcom, INC. | $15.86 | 2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $15.37 | 2025 | Ibsrela |
| Qol Medical, LLC | $12.25 | 2022 | |
| Organon LLC | $12.11 | 2024 | |
| Phathom Pharmaceuticals, INC. | $9.54 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manojkumar Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.